ACRV Stock — Acrivon Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$2.15

Market cap

$92.13M

Price action

19 metrics

Price change (1W)

-5.0%

Price change (30D)

+32.7%

Price change (3M)

+31.8%

Price change (6M)

+24.0%

Price change (YTD)

-14.1%

Price change (1Y)

+54.5%

Trailing year

Price change (5Y)

—

52-week high

$3.01

52-week low

$1.29

Change from 52-week high

-31.2%

Change from 52-week low

+60.5%

Annualized volatility

95.4%

Beta

2.0

RSI (14D)

56.4

Price vs SMA 50

+13.0%

Price vs SMA 200

+11.4%

Avg volume (3M)

397,491

Relative volume

0.9

Average dollar volume

$718,074

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

42.85M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

1.0

reciprocal yield 97.9%

FCF yield

-72.5%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-83.9%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-05-26

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$78.37M

Net income (TTM)

−$74.22M

Trailing 12 months

Diluted EPS (TTM)

$-1.88

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-13.45

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+8.8%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-85.6%

Return on assets

-74.9%

Debt / equity

—

Current ratio

8.0

EBITDA (TTM)

—

Free cash flow (TTM)

−$64.14M

Quick ratio

8.0

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$89.96M

Latest balance sheet

Cash & equivalents

$41.42M

Total assets

$99.09M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$62.92M

Capital expenditures (TTM)

$1.22M

R&D (TTM)

$57.40M

SG&A (TTM)

—

Stock compensation (TTM)

$11.40M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

46

13F filer change QoQ

+2

Institutional ownership

49.9%

Short interest

3 metrics

Short interest

2.9%

Latest settlement · 4.1 days to cover

Days to cover

4.1d

Short-squeeze score

62 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$39,806

Insider-sentiment score

31 / 100

Risk flags

1 metrics

Going concern

—

ACRV · Acrivon Therapeutics, Inc.

ACRV metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search